80 citations
,
January 1995 in “The Nephron journals/Nephron journals” This study concluded that a sequential regimen of prednisolone and cyclophosphamide, followed by low-dose prednisolone and azathioprine, achieved favorable results in most patients with diffuse proliferative and/or membranous lupus nephritis without significant toxicities.
52 citations
,
September 2021 in “Kidney International” In this report, a 23-year-old woman developed nephrotic syndrome and was diagnosed with lupus nephritis after receiving the first dose of the AstraZeneca COVID-19 vaccine, but causation is not established.
19 citations
,
December 2008 in “Arthritis Care & Research” This study found that the decision board is a reliable and valid tool for assessing treatment preferences in systemic lupus erythematosus patients, who tended to favor oral medication due to concerns about side effects.
12 citations
,
October 2016 in “Patient Preference and Adherence” This study found that both patients and physicians expressed dissatisfaction with disease control in systemic lupus erythematosus, with patients showing greater dissatisfaction than physicians regarding symptoms.
11 citations
,
March 2010 in “PubMed” This study concluded that monthly pulse IV cyclophosphamide therapy was effective in achieving complete or partial remission in 68.9% of Indian patients with severe lupus nephritis, though longer follow-up is needed.